Table 2.
Baseline characteristics
| DOAC (n = 48) | Warfarin (n = 107) | p value | |
|---|---|---|---|
|
| |||
| CHA2DS2-VASc score | |||
| 0 | 11 (22.9) | 16 (15.0) | 0.25 |
| 1 | 13 (27.1) | 39 (36.4) | |
| 2 | 12 (25.0) | 23 (21.4) | |
| 3 | 8 (16.7) | 18 (16.8) | |
| 4 | 2 ( 4.2) | 6 (5.6) | |
| 5 | 2 ( 4.2) | 0 | |
| N/A | 0 | 5 (4.7) | |
| NYHA classification | |||
| No CHF | 18 (37.5) | 61 (57.0) | 0.15 |
| 1 | 7 (14.6) | 11 (10.3) | |
| 2 | 17 (35.4) | 28 (26.2) | |
| 3 | 6 (12.5) | 7 (6.5) | |
| HASBLED score | |||
| 0 | 22 (45.8) | 38 (35.5) | 0.61 |
| 1 | 15 (31.3) | 33 (30.8) | |
| 2 | 10 (20.8) | 23 (21.5) | |
| 3 | 1 ( 2.1) | 5 (4.7) | |
| 4 | 0 | 3 (2.8) | |
| N/A | 0 | 5 (4.7) | |
| Bleed Hx | 2 (4.2) | 5 (4.7)† | 1.00 |
| TE Hx | 11 (22.9) | 27 (25.2)* | 0.84 |
| Diabetes mellitus | 2 (4.2) | 4 (3.7)* | 1.00 |
| Renal dysfunction | 2 (4.2) | 4 (3.7) | 1.00 |
| Liver disease | 14 (29.2) | 30 (28.0) | 1.00 |
| Labile INR | 4 (8.3)* | 7 (6.5) | 0.74 |
Values are n (%). Bleed Hx, bleed history or predisposition; CHF, congestive heart failure; TE Hx, history of thrombotic/embolic complications; INR, international normalized ratio.
One patient converted to positive history during therapy re-initiation.
The number of warfarin patients with a bleed history/predisposition is underestimated because 7 patients initially did not have a bleed history/predisposition, and then had a bleeding event while on warfarin, and were ultimately restarted on warfarin because of high TE risk. Including these 7 patients who re-started warfarin after a bleeding event increases the proportion of warfarin patients with a bleed history/predisposition from 4.7 to 11.2%, although the p value is not statistically significant when compared to DOAC patients (p = 0.23)